AcelRx Pharmaceuticals

375 articles with AcelRx Pharmaceuticals

• AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

  3/15/2021

   AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its fourth quarter

• AcelRx to Host Fourth Quarter and Full Year 2020 Financial Results Call and Webcast on March 15, 2021

  3/8/2021

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter financial results after market close on Monday, March 15, 2021

• AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Patients Undergoing Plastic Surgery Procedures

  2/17/2021

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an agreement with Newport Plastic and Reconstructive Surgery Associates for an investigator-initiated study

• AcelRx Announces Pricing of $27.5 Million Public Offering of Common Stock

  1/20/2021

   AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced the pricing of its underwritten public offering of 14.5 million shares of its common stock for gross proceeds of

• AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Cardiac Surgery Enhanced Recovery Regimen

  1/19/2021

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), today announced an investigator-initiated study with University Hospitals (UH) Cleveland Medical Center that will evaluate the postoperative use of DSUVIA in a prospective cohort of patients undergoing cardiac surgery with cardiopulmonary bypass following a specialized enhanced recovery protocol.

• AcelRx Announces Underwritten Public Offering of Common Stock

  1/19/2021

  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an underwritten public offering of its common stock.

• AcelRx Announces Year-End 2020 Metrics and Review of 2020 Achievements

  1/14/2021

  AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, announced preliminary unaudited financial results and other information in connection with its participation in investor presentations, meetings and events during the week of the 39th Annual J.P. Morgan Healthcare Conference.

• AcelRx Announced $10 Million Registered Direct Common Stock Offering

  12/10/2020

   AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced it has entered into

• AcelRx Pharmaceuticals Announces Publication of Clinical Data on Decreased Postoperative Opioid Requirements and Enhanced Postanesthesia Recovery Following Perioperative Use of DSUVIA®

  12/10/2020

   AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication by the Journal of Universal Surgery of clinical data on the use of DSUVIA for acute perioperative

• AcelRx Pharmaceuticals to Present at LD Micro Main Event

  12/9/2020

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management will be providing an overview of the business and company updates at the LD Micro Main Event to be held December 14 at 1:40 p.m. ET (10:40 a.m. PT)

• AcelRx Pharmaceuticals Announces Partnership with the National Rural Health Association

  12/4/2020

  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced a partnership with the National Rural Health Association (NRHA) focused on the co-development and execution of a strategic marketing plan to educate and promote DSUVIA

• AcelRx Pharmaceuticals Announces Commentary in Practical Pain Management on Previously Published Clinical Data on Preoperative Administration of DSUVIA®

  11/18/2020

  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the recent publication by Practical Pain Management of a commentary discussing the benefits of using DSUVIA for acute pain management.

• AcelRx Pharmaceuticals to Present at Credit Suisse 29th Annual Virtual Healthcare Conference

  11/6/2020

   AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management will be presenting at the Credit Suisse 29 th Annual Virtual Healthcare Conference to be held

• AcelRx Pharmaceuticals Reports Third Quarter 2020 Financial Results

  11/5/2020

  The Zimmer Biomet collaboration, addition of DSUVIA® to the U.S. Department of Defense Joint Deployment Formulary and the U.S. Army contract highlight third quarter achievements and growth opportunities

• AcelRx to Host Third Quarter 2020 Financial Results Call and Webcast on Thursday, November 5, 2020

  10/29/2020

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close on Thursday, November 5, 2020 . AcelRx management will host a live webcast and conference call at 4:30 p.m. Eastern Time ( 1:30 p.m. Pacific Time ) on Nov

• AcelRx Awarded U.S. Army Contract for DSUVIA®

  9/22/2020

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), today announced that the U.S. Army has awarded AcelRx with an initial contract of up to approximately $3.6 million for the purchase of DSUVIA to support a study to aid the development of clinical practice guidelines.

• AcelRx Announces DSUVIA® Added to the U.S. Department of Defense's Joint Deployment Formulary

  9/14/2020

  DSUVIA now available to all branches of the military Availability expanded beyond Milestone C approval for Army sets, kits and outfits

• AcelRx Pharmaceuticals to Present at Two Upcoming Conferences

  9/10/2020

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will be providing an overview of the business and company updates at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference

• AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Orthopedic Patients in the Perioperative Setting

  8/24/2020

   AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an investigator-initiated study with Cleveland Clinic.  The study will assess the effects of DSUVIA on post-o

• AcelRx Pharmaceuticals Announces Publication of Clinical Data on Reduced Opioid Use and Reduced Time in the Postanesthesia Care Unit (PACU) Following Preoperative Administration of DSUVIA®

  8/19/2020

  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a study entitled "Reduced Opioid Use and Reduced Time in the Postanesthesia Care Unit Following Pr